270 related articles for article (PubMed ID: 31771654)
1. Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment.
Tubin S; Khan MK; Salerno G; Mourad WF; Yan W; Jeremic B
Radiat Oncol; 2019 Nov; 14(1):212. PubMed ID: 31771654
[TBL] [Abstract][Full Text] [Related]
2. Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment.
Tubin S; Ashdown M; Jeremic B
Radiat Oncol; 2019 Dec; 14(1):220. PubMed ID: 31801549
[TBL] [Abstract][Full Text] [Related]
3. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.
Tubin S; Popper HH; Brcic L
Radiat Oncol; 2019 Jan; 14(1):21. PubMed ID: 30696472
[TBL] [Abstract][Full Text] [Related]
4. Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY).
Tubin S; Gupta S; Grusch M; Popper HH; Brcic L; Ashdown ML; Khleif SN; Peter-Vörösmarty B; Hyden M; Negrini S; Fossati P; Hug E
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375357
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
8. The impact of histology in the outcomes of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) and adjuvant chemotherapy.
Ernani V; Appiah AK; Baine MJ; Smith LM; Ganti AK
Cancer Treat Res Commun; 2020; 24():100197. PubMed ID: 32777751
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
10. Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early stage lung cancer.
Parashar B; Port J; Arora S; Christos P; Trichter S; Nori D; Wernicke AG
Brachytherapy; 2015; 14(5):648-54. PubMed ID: 25998071
[TBL] [Abstract][Full Text] [Related]
11. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
[TBL] [Abstract][Full Text] [Related]
12. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.
Sun Y; Duan Q; Chen X; Chen W; Jin X; Wu R
Clin Transl Oncol; 2017 Dec; 19(12):1498-1506. PubMed ID: 28589432
[TBL] [Abstract][Full Text] [Related]
14. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis.
Verma V; Simone CB; Allen PK; Lin SH
Clin Lung Cancer; 2017 Nov; 18(6):675-681.e1. PubMed ID: 28408183
[TBL] [Abstract][Full Text] [Related]
16. Definitive treatment patterns and survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Suzuki K; Dyer M; Truong MT; Litle V; Mak KS
Lung Cancer; 2018 Oct; 124():135-142. PubMed ID: 30268452
[TBL] [Abstract][Full Text] [Related]
17. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
18. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
